Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn’s disease

Abstract

BackgroundCrohn’s disease (CD) has an unclear etiology, but there is growing evidence of a direct link with a dysbiotic microbiome. Many gut microbes have previously been associated with CD, but these have mainly been confounded with patients’ ongoing treatments. Additionally, most analyses of CD patients’ microbiomes have focused on microbes in stool samples, which yield different insights than profiling biopsy samples.ResultsWe sequenced the 16S rRNA gene (16S) and carried out shotgun metagenomics (MGS) from the intestinal biopsies of 20 treatment-naïve CD and 20 control pediatric patients. We identified the abundances of microbial taxa and inferred functional categories within each dataset. We also identified known human genetic variants from the MGS data. We then used a machine learning approach to determine the classification accuracy when these datasets, collapsed to different hierarchical groupings, were used independently to classify patients by disease state and by CD patients’ response to treatment. We found that 16S-identified microbes could classify patients with higher accuracy in both cases. Based on follow-ups with these patients, we identified which microbes and functions were best for predicting disease state and response to treatment, including several previously identified markers. By combining the top features from all significant models into a single model, we could compare the relative importance of these predictive features. We found that 16S-identified microbes are the best predictors of CD state whereas MGS-identified markers perform best for classifying treatment response.ConclusionsWe demonstrate for the first time that useful predictors of CD treatment response can be produced from shotgun MGS sequencing of biopsy samples despite the complications related to large proportions of host DNA. The top predictive features that we identified in this study could be useful for building an improved classifier for CD and treatment response based on sufferers’ microbiome in the future.The BISCUIT project is funded by a Clinical Academic Fellowship from the Chief Scientist Office (Scotland)—CAF/08/01.Electronic supplementary materialThe online version of this article (10.1186/s40168-018-0398-3) contains supplementary material, which is available to authorized users.

A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases

“…The majority of data used was clinical, with very few papers utilising 'omic data. 86,[97][98][99] Monitoring and management Ten different studies of type 1 diabetes (T1D) used ML for monitoring and management: four predicted blood glucose level, four identified or predicted hypoglycaemic events, and two supported decision making using case-based reasoning or decision support systems. The majority of models used clinical data.…”

Deciphering the Ecology of Cystic Fibrosis Bacterial Communities: Towards Systems-Level Integration

“…Even if resultant findings cannot be used directly in clinical settings, such association is essential for developing mechanistic models that can be used for biomarker development or applied directly in clinical settings [90]. Machine learning approaches based on microbiome composition have been used in many diseases, including colorectal cancer [91,92], Crohn's disease [93], and nonalcoholic fatty liver disease [94]. However, the complexity of performing such studies has thus far limited the utility and generalizability of their predictive outcomes.…”

Peer Review #1 of "Denoising the Denoisers: an independent evaluation of microbiome sequence error-correction approaches (v0.1)"

“…The Extreme dataset was sequenced using an Illumina MiSeq (Callahan et al, 2016) and the fungal mock community was sequenced using an Illumina HiSeq (Bokulich et al, 2016). The soil data set collected from blueberry fields (available under NCBI SRA PRJNA389786) and the exercise dataset collected from stool of mice that exercised plus controls (ENA accession PRJEB18615) (Lamoureux et al, 2017) as well as the humanassociated dataset of intestinal biopsies of pediatric Crohn's disease patients plus controls (ENA accession PRJEB21933) (Douglas et al, 2018) were sequenced at the Integrated Microbiome Resource at Dalhousie University.…”